BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years

Rhea-AI Summary

BD (Becton, Dickinson and Company) plans to invest approximately $1.2 billion over four years to enhance its manufacturing capacity for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across six global locations, including a new facility in Europe expected to be operational by 2023. This investment aims to improve supply continuity and accommodate increased demand from pharmaceutical companies for injectable drugs. BD has already expanded its capacity by 350 million units since 2018, reinforcing its leadership in the market.

Positive

• Investment of $1.2 billion will expand manufacturing capacity for pre-fillable syringes and advanced drug delivery systems.
• New manufacturing facility in Europe expected to be operational by end of 2023.
• Enhanced supply chain continuity for pharmaceutical companies relying on injectable drugs, particularly during pandemic responses.
• Increased manufacturing capacity by 350 million units since 2018 indicates strong growth potential.

Negative

• None.

FRANKLIN LAKES, N.J., Dec. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across its six global manufacturing locations and add a new manufacturing facility in Europe.

The new manufacturing facility in Europe is expected to be operational by the end of 2023. The investment will also fund capacity expansion, new product innovations, manufacturing technology enhancements and business continuity improvements across its existing network, all designed to maximize supply and reduce risks for pharmaceutical companies that rely on ready-to-fill syringes for their injectable drugs — including complex biologics, vaccines and small molecules.    

"BD invented the ready-to-fill, pre-fillable syringe technology, and today's announcement demonstrates our continued commitment to better serve our customers," said Eric Borin, worldwide president of BD Pharmaceutical Systems. "Since 2018, BD has added 350 million units of manufacturing capacity for glass barrel pre-fillable syringes, and this new commitment will invest in additional upgrades at all of our Pharmaceutical Systems manufacturing facilities and across multiple product categories. In addition, this investment positions BD to have the needed surge capacity for increased pre-fillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines. This significant investment in one of BD's fastest growing business units will further advance our leadership position and enable continued strong growth in the years ahead."

The six current manufacturing facilities for BD Pharmaceutical Systems that will see a portion of this investment include facilities in Columbus, Nebraska; Cuautitlán, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, United Kingdom; and Tatabánya, Hungary.  

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.

Contacts:

Troy Kirkpatrick
BD Public Relations
858.617.2361                                                          
troy.kirkpatrick@bd.com                                           

Kristen M. Stewart, CFA
BD Investor Relations
201.847.5378
kristen.stewart@bd.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-to-invest-1-2-billion-in-pre-fillable-syringe-manufacturing-capacity-over-next-four-years-301183196.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

What is BD's recent investment announcement?

BD announced it will invest $1.2 billion over four years to expand and upgrade manufacturing capacity for pre-fillable syringes and advanced drug delivery systems.

When will the new manufacturing facility in Europe be operational?

The new manufacturing facility in Europe is expected to be operational by the end of 2023.

What is the purpose of BD's $1.2 billion investment?

The investment aims to enhance manufacturing capacity, improve supply continuity, and accommodate increased demand for injectable drugs.

Where are BD's current manufacturing facilities located?

BD's current facilities include locations in Columbus, Nebraska; Cuautitlán, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, United Kingdom; and Tatabánya, Hungary.

How much manufacturing capacity has BD added since 2018?

Since 2018, BD has added 350 million units of manufacturing capacity for glass barrel pre-fillable syringes.